V5P.F VYTRUS BIOTECH EO -01

Healthcare Biotechnology Frankfurt Exchange
13.05 EUR
Close of Nov 12, 2026
7.00 21.60
Market cap
EUR 98.2M
P/E
23.7x
P/B
7.35x
ROE
28.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is V5P.F undervalued?

Graham number
Price13.05
Graham value4.69
Premium178.4%

V5P.F trades 178.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VYTRUS BIOTECH EO -01 fundamental analysis

No fundamental analysis for VYTRUS BIOTECH EO -01 yet.

VYTRUS BIOTECH EO -01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VYTRUS BIOTECH EO -01

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum …

Full company profile